Lantheus Holdings Inc LNTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
-
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)
-
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
-
Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders
-
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
-
Lantheus Application for Tumor Imaging Drug Rejected Due to Manufacturing Concerns
Trading Information
- Previous Close Price
- $100.98
- Day Range
- $100.59–101.07
- 52-Week Range
- $49.67–111.86
- Bid/Ask
- $100.55 / $101.21
- Shares Outstanding
- 65.27M
- Market Cap
- $6.57B
- Volume/Avg
- 4M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 16.92
- Price/Sales
- 4.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 2.99%
Company Profile
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,193
- Website
- https://www.lantheus.com
Valuation
|
Metric
|
LNTH
|
|---|---|
Price/Earnings (Normalized) | 16.92 |
Price/Book Value | 5.01 |
Price/Sales | 4.28 |
Price/Cash Flow | 16.91 |
Price/Earnings
LNTH
Financial Strength
|
Metric
|
LNTH
|
|---|---|
Quick Ratio | 2.82 |
Current Ratio | 3.06 |
Interest Coverage | 18.42 |
Quick Ratio
LNTH
Profitability
|
Metric
|
LNTH
|
|---|---|
Return on Assets (Normalized) | 12.67% |
Return on Equity (Normalized) | 24.44% |
Return on Invested Capital (Normalized) | 16.09% |
Return on Assets
LNTH
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|yjV!lC@P | LOCK|x!kd$ | $70B | |||
| Haleon PLC ADR
HLN
| LOCK|#B^$v#W | LOCK|l#G | $43B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|!$fpX%l@ | LOCK|G??## | $43B | |||
| Zoetis Inc Class A
ZTS
| LOCK|$D?tfh&N | LOCK|Y%$ | $31B | |||
| Viatris Inc
VTRS
| LOCK|QjWqMzD | LOCK|K@h | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|%%n | LOCK|K$N | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|>n!d@d | LOCK|tV | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|R>P%#$v | LOCK|t^ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|?frd%c | LOCK|>YZrY | $3B | |||
| Perrigo Co PLC
PRGO
| LOCK|p<$<f!$ | LOCK|<<< | $2B |
United States